secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001367644-23-000127
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions CEO Robert Kramer retires; Haywood Miller named interim CEO
--------------------------------------------------------------------------------

- Robert Kramer resigned as President/CEO and director effective June 24, 2023; will advise until Aug 1.
- Haywood Miller, managing director at Berkeley Research Group, appointed interim CEO immediately.
- Miller receives $125K/month cash compensation until permanent CEO is named or June 24, 2024.
- Board to conduct search for permanent CEO with assistance from executive search firm.
- Company highlights 2023 transformation including sale of travel health business and ACAM2000 contract extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000127/0001367644-23-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000127/ebs-20230623.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer